Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib, Lenalidomide, and Dexamethasone in Multiple Myeloma
NCT03015792Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Mar 2017
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose at 28 days and Overall Response Rate at 3 years. Started Mar 2017; status: terminated.
02
Drugs
ibrutinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03015792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015792.